Volume 28, Number 10—October 2022
Research
SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
Table 4
Variables most associated with a Delta variant infection in 2 analyses of SARS-CoV-2 vaccine breakthrough during the emergence period of the Delta variant, New York, USA*
Model | ΔAIC | Parameter 1 | Parameter 2 | Parameter 3 |
---|---|---|---|---|
Main analysis | ||||
Vaccination status | 0.00 | Vaccinated: 2.4 (0.8–6.8) | ||
Vaccine type |
1.05 |
Pfizer: 2.86 (0.92–8.94) |
Moderna: 0.38 (0.04–4.20) |
Janssen: 1.97 (0.17–23.57) |
Age analysis | ||||
Vaccine type | 0.02 | Pfizer: 7.3 (2.0–26.7)† | Moderna: 2.0 (0.25–17.1) | Janssen: 0.46 (0.04–4.76) |
*None of the main analysis models were statistically significant because all 95% CIs for odds ratio estimates overlapped 1. Janssen vaccine, Janssen/Johnson & Johnson (https://www.jnj.com); Pfizer vaccine, Pfizer-BioNTech (https://www.pfizer.com); Moderna vaccine, Moderna (https://www.modernatx.com). ΔAIC, change in Akaike information criterion. †p<0.01.